Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6181014 | 0.80 | ENPP2 (0.49) | ENPP2PTGS2EPHX2NR1H4 | |
| SCHEMBL6182049 | 0.77 | PTGS2 (0.43) | ENPP2PTGS2EPHX2NR1H4 | |
| SCHEMBL2600037 | 0.75 | ESR1 (0.50) | ENPP2PTGS2EPHX2NR1H4KCNJ1 | |
| SCHEMBL1575569 | 0.74 | NPY5R (0.40) | ENPP2PTGS2EPHX2NR1H4DAO | |
| SCHEMBL8363191 | 0.74 | ENPP2 (0.42) | ENPP2PTGS2EPHX2NR1H4KCNJ1 | |
| SCHEMBL398570 | 0.74 | ENPP2 (0.50) | ENPP2PTGS2CYP3A4CYP2C9KCNJ1 | |
| SCHEMBL13231429 | 0.73 | ENPP2 (0.54) | ENPP2PTGS2 | |
| SCHEMBL6182058 | 0.73 | ENPP2 (0.41) | ENPP2PTGS2EPHX2NR1H4PTGDR2 | |
| SCHEMBL2376239 | 0.72 | ENPP2 (0.72) | ENPP2PTGS2 | |
| SCHEMBL11773990 | 0.72 | IDO1 (0.44) | CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919353-B2 | Substituted 8-arylquinolune PDE4 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2005-07-19 | — | — | US | disclosed |
| EP-1404330-B1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-06-01 | — | — | EP | disclosed |
| US-20040162314-A1 | Substituted 8-arylquinolune pde4 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2004-08-19 | — | — | US | disclosed |
| EP-1404330-A1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003002118-A1 | SUBSTITUTED 8-ARYLQUINOLINE PDE4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162314-A1 | Substituted 8-arylquinolune pde4 inhibitors | PDE12, PDE4A, PDE4B | ENPP2 941/4885PTGS2 382/4885EPHX2 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.